| Rank |
Clinical Trial |
PubWeight™‹?› |
|
101
|
Genetic Architecture of Plasma T-PA and PAI-1
|
60.28
|
|
102
|
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
|
59.26
|
|
103
|
Diabetes Prevention Program
|
58.96
|
|
104
|
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
|
58.55
|
|
105
|
Secondary Prevention of Small Subcortical Strokes Trial (SPS3)
|
58.05
|
|
106
|
Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (LCA)
|
57.82
|
|
107
|
Asthma Clinical Research Network (ACRN)
|
57.63
|
|
108
|
Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis
|
57.43
|
|
109
|
Systolic Blood Pressure Intervention Trial (SPRINT)
|
56.84
|
|
110
|
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease (STICH)
|
56.53
|
|
111
|
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
|
56.51
|
|
112
|
Effect of Male Circumcision on HIV Incidence (ANRS 1265)
|
56.51
|
|
113
|
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
|
55.92
|
|
114
|
Bicalutamide in Treating Patients With Metastatic Breast Cancer
|
55.84
|
|
115
|
A Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
|
55.80
|
|
116
|
Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (Dry AMD)
|
55.39
|
|
117
|
Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
|
55.37
|
|
118
|
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia (IPASS)
|
55.10
|
|
119
|
Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community
|
55.10
|
|
120
|
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE)
|
55.09
|
|
121
|
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
|
55.08
|
|
122
|
Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV
|
55.06
|
|
123
|
The Research Registry for Neonatal Lupus
|
54.78
|
|
124
|
Insulin Resistance Atherosclerosis Study (IRAS)
|
54.77
|
|
125
|
Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure
|
54.50
|
|
126
|
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
54.39
|
|
127
|
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications (SAVOR- TIMI 53)
|
53.70
|
|
128
|
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
|
53.18
|
|
129
|
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
|
53.07
|
|
130
|
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
|
52.55
|
|
131
|
Women's Ischemia Syndrome Evaluation (WISE)
|
52.45
|
|
132
|
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)
|
52.45
|
|
133
|
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)
|
52.30
|
|
134
|
Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) (VADT)
|
52.28
|
|
135
|
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
|
52.05
|
|
136
|
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)
|
52.04
|
|
137
|
Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy
|
51.98
|
|
138
|
Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence (SISTEr)
|
51.98
|
|
139
|
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
|
51.86
|
|
140
|
Strategic Timing of Antiretroviral Treatment (START)
|
51.73
|
|
141
|
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
|
51.61
|
|
142
|
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
|
51.09
|
|
143
|
Longitudinal Study of Ocular Complications of AIDS (LSOCA) (LSOCA)
|
50.58
|
|
144
|
Inflammation and the Host Response to Injury (Trauma)
|
50.53
|
|
145
|
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
|
50.46
|
|
146
|
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)
|
50.24
|
|
147
|
A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare
|
49.76
|
|
148
|
Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer (BIG 1-98)
|
49.73
|
|
149
|
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
|
49.69
|
|
150
|
S0000 Selenium and Vitamin E in Preventing Prostate Cancer (SELECT)
|
49.25
|
|
151
|
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
|
49.02
|
|
152
|
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
|
48.93
|
|
153
|
ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE)
|
48.66
|
|
154
|
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
|
48.45
|
|
155
|
Neighborhood Environments and Cardiovascular Disease
|
48.23
|
|
156
|
Infant Aphakia Treatment Study (IATS) (IATS)
|
48.11
|
|
157
|
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
|
47.94
|
|
158
|
A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
|
47.90
|
|
159
|
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v)
|
47.32
|
|
160
|
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk (REDUCE)
|
47.27
|
|
161
|
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
|
47.16
|
|
162
|
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
|
46.99
|
|
163
|
Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA) (MTA)
|
46.87
|
|
164
|
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)
|
46.83
|
|
165
|
Male Circumcision and HIV Rates in Kenya
|
46.81
|
|
166
|
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
|
46.59
|
|
167
|
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
|
46.44
|
|
168
|
Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (TECOS)
|
45.50
|
|
169
|
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
|
45.17
|
|
170
|
Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study (APACE)
|
44.96
|
|
171
|
Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)
|
44.88
|
|
172
|
Inflammation, Infection, and Future Cardiovascular Risk
|
44.83
|
|
173
|
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
|
44.77
|
|
174
|
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
|
44.59
|
|
175
|
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
|
44.56
|
|
176
|
Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)
|
44.37
|
|
177
|
Safety Study of Nivolumab by Itself or in Combination in Patients With Lymphoma or Multiple Myeloma
|
44.33
|
|
178
|
Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer (CRTCOESC)
|
44.33
|
|
179
|
Target Temperature Management After Cardiac Arrest (TTM)
|
44.29
|
|
180
|
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
|
44.27
|
|
181
|
Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women
|
44.01
|
|
182
|
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
43.96
|
|
183
|
A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)
|
43.64
|
|
184
|
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
|
43.53
|
|
185
|
A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
|
43.16
|
|
186
|
Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)
|
43.06
|
|
187
|
Trastuzumab in Treating Women With Primary Breast Cancer
|
43.00
|
|
188
|
Molecular Genetics of Schizophrenia
|
42.93
|
|
189
|
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
|
42.84
|
|
190
|
Occluded Artery Trial (OAT) (OAT)
|
42.74
|
|
191
|
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
|
42.56
|
|
192
|
Rapid Antidepressant Effects of Ketamine in Major Depression
|
42.55
|
|
193
|
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
|
42.35
|
|
194
|
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
|
42.28
|
|
195
|
Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia
|
42.06
|
|
196
|
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
|
42.03
|
|
197
|
Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE - SUGAR STUDY)
|
41.90
|
|
198
|
National Emphysema Treatment Trial (NETT)
|
41.86
|
|
199
|
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
|
41.85
|
|
200
|
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO-2)
|
41.74
|